Advertisement
Screener

Celldex Therapeutics, Inc. (CLDX) Operating Lease, Expense

2.8 / 5 stars · 68/120 Roast Me

Celldex Therapeutics, Inc. Operating Lease, Expense

Celldex Therapeutics, Inc. (CLDX) reported Operating Lease, Expense of $4.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.

Discontinued › Expense Statement › Operating Expenses

us-gaap:OperatingLeaseExpense · last filed 2019-03-07

  • Celldex Therapeutics, Inc. operating lease, expense for fiscal 2018 was $4.00M, a 2.44% decline from fiscal 2017.
  • Celldex Therapeutics, Inc. operating lease, expense for fiscal 2017 was $4.10M, a 14.58% decline from fiscal 2016.
  • Celldex Therapeutics, Inc. operating lease, expense for fiscal 2016 was $4.80M.
Period endOperating Lease, Expense 12 month
2018-12-31$4.00M
10-K · filed 2019-03-07
2017-12-31$4.10M
10-K · filed 2019-03-07
2016-12-31$4.80M
10-K · filed 2019-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93